Cargando…
Immune determinants of Barrett’s progression to esophageal adenocarcinoma
Esophageal adenocarcinoma (EAC) develops from Barrett’s esophagus (BE), a chronic inflammatory state that can progress through a series of transformative dysplastic states before tumor development. While molecular and genetic changes of EAC tumors have been studied, immune microenvironment changes d...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821593/ https://www.ncbi.nlm.nih.gov/pubmed/33290281 http://dx.doi.org/10.1172/jci.insight.143888 |
_version_ | 1783639456064995328 |
---|---|
author | Lagisetty, Kiran H. McEwen, Dyke P. Nancarrow, Derek J. Schiebel, Johnathon G. Ferrer-Torres, Daysha Ray, Dipankar Frankel, Timothy L. Lin, Jules Chang, Andrew C. Kresty, Laura A. Beer, David G. |
author_facet | Lagisetty, Kiran H. McEwen, Dyke P. Nancarrow, Derek J. Schiebel, Johnathon G. Ferrer-Torres, Daysha Ray, Dipankar Frankel, Timothy L. Lin, Jules Chang, Andrew C. Kresty, Laura A. Beer, David G. |
author_sort | Lagisetty, Kiran H. |
collection | PubMed |
description | Esophageal adenocarcinoma (EAC) develops from Barrett’s esophagus (BE), a chronic inflammatory state that can progress through a series of transformative dysplastic states before tumor development. While molecular and genetic changes of EAC tumors have been studied, immune microenvironment changes during Barrett’s progression to EAC remain poorly understood. In this study, we identify potential immunologic changes that can occur during BE-to-EAC progression. RNA sequencing (RNA-Seq) analysis on tissue samples from EAC patients undergoing surgical resection demonstrated that a subset of chemokines and cytokines, most notably IL6 and CXCL8, increased during BE progression to EAC. xCell deconvolution analysis investigating immune cell population changes demonstrated that the largest changes in expression during BE progression occurred in M2 macrophages, pro–B cells, and eosinophils. Multiplex immunohistochemical staining of tissue microarrays showed increased immune cell populations during Barrett’s progression to high-grade dysplasia. In contrast, EAC tumor sections were relatively immune poor, with a rise in PD-L1 expression and loss of CD8(+) T cells. These data demonstrate that the EAC microenvironment is characterized by poor cytotoxic effector cell infiltration and increased immune inhibitory signaling. These findings suggest an immunosuppressive microenvironment, highlighting the need for further studies to explore immune modulatory therapy in EAC. |
format | Online Article Text |
id | pubmed-7821593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-78215932021-01-25 Immune determinants of Barrett’s progression to esophageal adenocarcinoma Lagisetty, Kiran H. McEwen, Dyke P. Nancarrow, Derek J. Schiebel, Johnathon G. Ferrer-Torres, Daysha Ray, Dipankar Frankel, Timothy L. Lin, Jules Chang, Andrew C. Kresty, Laura A. Beer, David G. JCI Insight Research Article Esophageal adenocarcinoma (EAC) develops from Barrett’s esophagus (BE), a chronic inflammatory state that can progress through a series of transformative dysplastic states before tumor development. While molecular and genetic changes of EAC tumors have been studied, immune microenvironment changes during Barrett’s progression to EAC remain poorly understood. In this study, we identify potential immunologic changes that can occur during BE-to-EAC progression. RNA sequencing (RNA-Seq) analysis on tissue samples from EAC patients undergoing surgical resection demonstrated that a subset of chemokines and cytokines, most notably IL6 and CXCL8, increased during BE progression to EAC. xCell deconvolution analysis investigating immune cell population changes demonstrated that the largest changes in expression during BE progression occurred in M2 macrophages, pro–B cells, and eosinophils. Multiplex immunohistochemical staining of tissue microarrays showed increased immune cell populations during Barrett’s progression to high-grade dysplasia. In contrast, EAC tumor sections were relatively immune poor, with a rise in PD-L1 expression and loss of CD8(+) T cells. These data demonstrate that the EAC microenvironment is characterized by poor cytotoxic effector cell infiltration and increased immune inhibitory signaling. These findings suggest an immunosuppressive microenvironment, highlighting the need for further studies to explore immune modulatory therapy in EAC. American Society for Clinical Investigation 2021-01-11 /pmc/articles/PMC7821593/ /pubmed/33290281 http://dx.doi.org/10.1172/jci.insight.143888 Text en © 2021 Lagisetty et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Lagisetty, Kiran H. McEwen, Dyke P. Nancarrow, Derek J. Schiebel, Johnathon G. Ferrer-Torres, Daysha Ray, Dipankar Frankel, Timothy L. Lin, Jules Chang, Andrew C. Kresty, Laura A. Beer, David G. Immune determinants of Barrett’s progression to esophageal adenocarcinoma |
title | Immune determinants of Barrett’s progression to esophageal adenocarcinoma |
title_full | Immune determinants of Barrett’s progression to esophageal adenocarcinoma |
title_fullStr | Immune determinants of Barrett’s progression to esophageal adenocarcinoma |
title_full_unstemmed | Immune determinants of Barrett’s progression to esophageal adenocarcinoma |
title_short | Immune determinants of Barrett’s progression to esophageal adenocarcinoma |
title_sort | immune determinants of barrett’s progression to esophageal adenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821593/ https://www.ncbi.nlm.nih.gov/pubmed/33290281 http://dx.doi.org/10.1172/jci.insight.143888 |
work_keys_str_mv | AT lagisettykiranh immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT mcewendykep immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT nancarrowderekj immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT schiebeljohnathong immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT ferrertorresdaysha immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT raydipankar immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT frankeltimothyl immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT linjules immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT changandrewc immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT krestylauraa immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma AT beerdavidg immunedeterminantsofbarrettsprogressiontoesophagealadenocarcinoma |